Publication Name	World Journal of Hepatology
Manuscript ID	93028
Country	United States

Received	2024-02-17 01:48
Peer-Review Started	2024-02-17 01:48
To Make the First Decision
Return for Revision	2024-03-31 03:53
Revised	2024-04-08 19:40
Second Decision	2024-04-15 02:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-04-15 07:30
Articles in Press	2024-04-15 07:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-05-11 02:51
Publish the Manuscript Online	2024-05-22 11:33

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?
Manuscript Source	Invited Manuscript
All Author List	Howard D Lee and Li-Yun Yuan
Funding Agency and Grant Number
Corresponding Author	Howard D Lee, MD, Academic Fellow, Doctor, Doctor, Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, United States. howard.lee@med.usc.edu
Key Words	Hepatocellular carcinoma; Nanomedicine; Ligand-receptor mediated nanotherapy; Precision medicine; Personalized medicine; Targeting
Core Tip	Despite recent advances in locoregional and systemic therapy for the treatment of hepatocellular carcinoma, current conventional treatment of advanced disease only offers limited survival benefit. Systemic therapy is particularly constrained by the inability for precise targeting of tumor cells, thus leading to systemic adverse effects and decreased efficacy in treatment. Nanotherapy holds the potential to overcome these traditional constraints but remains primarily a proof of concept at this juncture with in vivo studies in animal models. Further research and collaboration will ultimately lead to clinical applicability.
Publish Date	2024-05-22 11:33
Citation	<p>Lee HD, Yuan LY. Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet? <i>World J Hepatol</i> 2024; 16(5): 684-687</p>
URL	https://www.wjgnet.com/1948-5182/full/v16/i5/684.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i5.684

Full Article (PDF)	WJH-16-684-with-cover.pdf
Manuscript File	93028_Auto_Edited-YJP.docx
Answering Reviewers	93028-Answering reviewers.pdf
Audio Core Tip	93028-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	93028-Conflict-of-interest statement.pdf
Copyright License Agreement	93028-Copyright license agreement.pdf
Peer-review Report	93028-Peer-review(s).pdf
Scientific Misconduct Check	93028-Bing-Che XX-2.png
Scientific Misconduct Check	93028-CrossCheck.png
Scientific Editor Work List	93028-Scientific editor work list.pdf
CrossCheck Report	93028-CrossCheck report.pdf